SRSF2 and myelodysplastic syndrome: Despite the well-known key prognostic significance that percentage of BM blasts plays in MDS, patients with isolated +8 and mutations in STAG2, SRSF2 and/or RUNX1 showed similar outcomes to high/very high-risk control patients, even with significant lower levels of blasts in BM (Table S5).